{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:47:20Z","timestamp":1790632040977,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,29]]},"DOI":"10.7759\/cureus.46185","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T10:49:17Z","timestamp":1695984557000},"source":"Crossref","is-referenced-by-count":9,"title":["Eculizumab Versus Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Kamran","family":"Shahid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Qayyum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2017.7053","article-title":"Atypical hemolytic uremic syndrome: a brief review","volume":"9","author":"Zhang K","year":"2017","unstructured":"Zhang K, Lu Y, Harley KT, Tran MH. Atypical hemolytic uremic syndrome: a brief review. Hematol Rep. 2017, 9:7053. 10.4081\/hr.2017.7053","journal-title":"Hematol Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience","volume":"109","author":"Sheerin NS","year":"2016","unstructured":"Sheerin NS, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM. 2016, 109:27-33. 10.1093\/qjmed\/hcv082","journal-title":"QJM"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2015.07.005","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document","volume":"35","author":"Campistol JM","year":"2015","unstructured":"Campistol JM, Arias M, Ariceta G, et al.. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2015, 35:421-47. 10.1016\/j.nefro.2015.07.005","journal-title":"Nefrologia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012862.pub2","article-title":"Interventions for atypical haemolytic uraemic syndrome","volume":"3","author":"Pugh D","year":"2021","unstructured":"Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev. 2021, 3:CD012862. 10.1002\/14651858.CD012862.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin D","year":"2010","unstructured":"Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010, 11:785-97. 10.1038\/ni.1923","journal-title":"Nat Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2009.08.006","article-title":"Paths reunited: Initiation of the classical and lectin pathways of complement activation","volume":"215","author":"Wallis R","year":"2010","unstructured":"Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH. Paths reunited: Initiation of the classical and lectin pathways of complement activation. Immunobiology. 2010, 215:1-11. 10.1016\/j.imbio.2009.08.006","journal-title":"Immunobiology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.11.003","article-title":"The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb)","volume":"45","author":"Bexborn F","year":"2008","unstructured":"Bexborn F, Andersson PO, Chen H, Nilsson B, Ekdahl KN. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol. 2008, 45:2370-9. 10.1016\/j.molimm.2007.11.003","journal-title":"Mol Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-010-1556-4","article-title":"aHUS caused by complement dysregulation: new therapies on the horizon","volume":"26","author":"Waters AM","year":"2011","unstructured":"Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011, 26:41-57. 10.1007\/s00467-010-1556-4","journal-title":"Pediatr Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht C","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, et al.. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015, 87:1061-73. 10.1038\/ki.2014.423","journal-title":"Kidney Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5551\/jat.RV17026","article-title":"Pathogenesis of atypical hemolytic uremic syndrome","volume":"26","author":"Yoshida Y","year":"2019","unstructured":"Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of atypical hemolytic uremic syndrome. J Atheroscler Thromb. 2019, 26:99-110. 10.5551\/jat.RV17026","journal-title":"J Atheroscler Thromb"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16297","article-title":"The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function","volume":"189","author":"Fujisawa M","year":"2020","unstructured":"Fujisawa M, Yasumoto A, Kato H, Sugawara Y, Yoshida Y, Yatomi Y, Nangaku M. The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function. Br J Haematol. 2020, 189:182-6. 10.1111\/bjh.16297","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis K","year":"2006","unstructured":"Ritis K, Doumas M, Mastellos D, et al.. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006, 177:4794-802. 10.4049\/jimmunol.177.7.4794","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13022","article-title":"Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis","volume":"30","author":"Legendre CM","year":"2017","unstructured":"Legendre CM, Campistol JM, Feldkamp T, et al.. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. Transpl Int. 2017, 30:1275-83. 10.1111\/tri.13022","journal-title":"Transpl Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-016-0288-3","article-title":"Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment","volume":"30","author":"Walle JV","year":"2017","unstructured":"Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017, 30:127-34. 10.1007\/s40620-016-0288-3","journal-title":"J Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome","volume":"30","author":"Zuber J","year":"2019","unstructured":"Zuber J, Frimat M, Caillard S, et al.. Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2019, 30:2449-63. 10.1681\/ASN.2019040331","journal-title":"J Am Soc Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau E","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, et al.. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2020, 97:1287-96. 10.1016\/j.kint.2020.01.035","journal-title":"Kidney Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-02190-0","article-title":"Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis","volume":"22","author":"G\u00e4ckler A","year":"2021","unstructured":"G\u00e4ckler A, Sch\u00f6nermarck U, Dobronravov V, et al.. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. BMC Nephrol. 2021, 22:5. 10.1186\/s12882-020-02190-0","journal-title":"BMC Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.03.884","article-title":"Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults","volume":"6","author":"Barbour T","year":"2021","unstructured":"Barbour T, Scully M, Ariceta G, et al.. Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep. 2021, 6:1603-13. 10.1016\/j.ekir.2021.03.884","journal-title":"Kidney Int Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5414\/CN110516","article-title":"Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data","volume":"97","author":"Tomazos I","year":"2022","unstructured":"Tomazos I, Hatswell AJ, Cataland S, et al.. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data. Clin Nephrol. 2022, 97:261-72. 10.5414\/CN110516","journal-title":"Clin Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell R","year":"2015","unstructured":"Cofiell R, Kukreja A, Bedard K, et al.. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015, 125:3253-62. 10.1182\/blood-2014-09-600411","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-022-00620-3","article-title":"Exploratory prognostic biomarkers of complement-mediated thrombotic microangiopathy (CM-TMA) in adults with atypical hemolytic uremic syndrome (aHUS): snalysis of a phase III study of ravulizumab","volume":"27","author":"Cammett TJ","year":"2023","unstructured":"Cammett TJ, Garlo K, Millman EE, Rice K, Toste CM, Faas SJ. Exploratory prognostic biomarkers of complement-mediated thrombotic microangiopathy (CM-TMA) in adults with atypical hemolytic uremic syndrome (aHUS): snalysis of a phase III study of ravulizumab. Mol Diagn Ther. 2023, 27:61-74. 10.1007\/s40291-022-00620-3","journal-title":"Mol Diagn Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12641","article-title":"Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens","volume":"22","author":"Krishnappa V","year":"2018","unstructured":"Krishnappa V, Gupta M, Elrifai M, et al.. Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens. Ther Apher Dial. 2018, 22:178-88. 10.1111\/1744-9987.12641","journal-title":"Ther Apher Dial"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri F","year":"2021","unstructured":"Fakhouri F, Fila M, Hummel A, et al.. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021, 137:2438-49. 10.1182\/blood.2020009280","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0036","article-title":"Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome","volume":"12","author":"Mauch TJ","year":"2023","unstructured":"Mauch TJ, Chladek MR, Cataland S, et al.. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. J Comp Eff Res. 2023, 12:e230036. 10.57264\/cer-2023-0036","journal-title":"J Comp Eff Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2027706","article-title":"Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"25","author":"Levy AR","year":"2022","unstructured":"Levy AR, Chen P, Johnston K, Wang Y, Popoff E, Tomazos I. Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Med Econ. 2022, 25:249-59. 10.1080\/13696998.2022.2027706","journal-title":"J Med Econ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/188184-eculizumab-versus-ravulizumab-for-the-treatment-of-atypical-hemolytic-uremic-syndrome-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:04Z","timestamp":1707509404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/188184-eculizumab-versus-ravulizumab-for-the-treatment-of-atypical-hemolytic-uremic-syndrome-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.46185","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}